«‹1234»Seite
4 articles with references, page 1 of 4

Original article

Trend Reversal in the Frequency of Mycoses in Hematological Neoplasias

Dtsch Arztebl Int 2008; 105(28-29): 501-6; DOI: 10.3238/arztebl.2008.0501

Donhuijsen, K; Petersen, P; Schmid, K W

1. Viscoli C, Girmenia C, Marinus A et al.: The Invasive Fungal Infection Group of the EORTC. Candidemia in cancer patients. A prospective, multicenter surveillance study in Europe by the the Invasive Fungal Infection Group (IFIG) of the European Organization für Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1071–9. MEDLINE
2. Ruhnke M, Boehme A, Buchheidt D et al.: Diagnosis of invasive fungal infections in hematology- and oncology-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82: 141–8. MEDLINE
3. Herbrecht R, Denning DW, Petterson TF et al.: Voriconazole versus Amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–15. MEDLINE
4. Mora-Duarte J, Betts R, Rotstein C et al.: Comparison of Caspofungin and Amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020–9. MEDLINE
5. De Pauw BE, Donnelly, JP: Prophylaxis and aspergillosis – has the principle been proven? N Engl J Med 2007; 356: 409–11. MEDLINE
6. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K: Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infection1996; 33: 23–32. MEDLINE
7. Schwesinger G, Junghans D, Schröder G, Bernhardt H, Knoke M: Candidosis and aspergillosis as autopsy findings from 1994 to 2003. Mycoses 2005; 48: 176–80. MEDLINE
8. Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ et al.: Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica 2006; 91: 986–9. MEDLINE
9. Kehrer E, Brandt G: Mykosen im Autopsiematerial: Häufigkeit, Lokalisationen und Ursachenspektrum. Mykosen 1970; 22: 280–8. MEDLINE
10. Bodey G, Bueltmann B, Duguid W et al.: Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11: 99–109. MEDLINE
11. Patterson TF, Kirkpatrick WR, White M et al.: Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine 2000; 79: 250–60. MEDLINE
12. DRST-Jahresberichte, Deutsches Register für Stammzelltransplantation; www.drst.de
13. Koldehoff M, Elmaagacli AH, Steckel NK et al.: Successful treatment of patients with respiratory failure due to fungal infection after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2005; 7: 137–45. MEDLINE
14. Trenschel R, Ditschkowski M, Elmaagacli AH et al.: Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allegeneic stem cell transplantation. Bone Marrow Transplant 2005; 35: 583–6. MEDLINE
15. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD et al.: Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clinical Infectious Diseases 2001; 33: 641–67. MEDLINE
16. Richardson M: Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 2005; 56: 5–11. MEDLINE
17. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A et al.: Posaconazole or Fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335–47. MEDLINE
18. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C et al.: Zygomycosis in a tertiary-care center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27. J Infect Dis 2005; 191: 1350–60. MEDLINE
19. Pagano L, Caira M, Candoni A et al.: The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004-study. Haematologica 2006; 91: 1068–75. MEDLINE
20. Upton A, Kirby KA, Capenter P, Boeckh M, Marr KA: Invasive Aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Inf Dis 2007; 44: 531–40. MEDLINE
21. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ et al.: Posaconazole vs. Fluconazole or Itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007, 356: 348–59. MEDLINE